Atezolizumab and bevacizumab

The global, open-label, phase III Imbrave150 trial (NCT03434379) included 501 patients with unresectable HCC who had not received prior systemic therapy. Patients were randomly assigned in a 2:1 ratio to receive either atezolizumab (1,200 mg intravenously [IV]) and bevacizumab (15mg/kg IV) every 3 weeks (n = 336) or sorafenib (400 mg PO bid) (n = 165). Eligibility criteria included intact liver function (Child-Pugh class A), and the study excluded patients with untreated or incompletely treated esophageal or gastric varices.[9]

The global, open-label, phase III Imbrave150 trial (NCT03434379) included 501 patients with unresectable HCC who had not received prior systemic therapy. Patients were randomly assigned in a 2:1 ratio to receive either atezolizumab (1,200 mg intravenously [IV]) and bevacizumab (15mg/kg IV) every 3 weeks (n = 336) or sorafenib (400 mg PO bid) (n = 165). Eligibility criteria included intact liver function (Child-Pugh class A), and the study excluded patients with untreated or incompletely treated esophageal or gastric varices.[9]

The OS was 19.2 months (95% confidence interval [CI], 17.0–23.7) in the atezolizumab-bevacizumab arm and 13.4 months (95% CI, 11.4–16.9) in the sorafenib arm (HR, 0.66; 95% CI, 0.52–0.85; P < .001).[9][Level of evidence A1]

The global, open-label, phase III Imbrave150 trial (NCT03434379) included 501 patients with unresectable HCC who had not received prior systemic therapy. Patients were randomly assigned in a 2:1 ratio to receive either atezolizumab (1,200 mg intravenously [IV]) and bevacizumab (15mg/kg IV) every 3 weeks (n = 336) or sorafenib (400 mg PO bid) (n = 165). Eligibility criteria included intact liver function (Child-Pugh class A), and the study excluded patients with untreated or incompletely treated esophageal or gastric varices.[9]

The objective response rates were 30% (95% CI, 25%–35%) in the atezolizumab-bevacizumab arm and 11% (95% CI, 7%–17%) in the sorafenib arm.

The global, open-label, phase III Imbrave150 trial (NCT03434379) included 501 patients with unresectable HCC who had not received prior systemic therapy. Patients were randomly assigned in a 2:1 ratio to receive either atezolizumab (1,200 mg intravenously [IV]) and bevacizumab (15mg/kg IV) every 3 weeks (n = 336) or sorafenib (400 mg PO bid) (n = 165). Eligibility criteria included intact liver function (Child-Pugh class A), and the study excluded patients with untreated or incompletely treated esophageal or gastric varices.[9]

In subgroup-analyses, the OS benefit was generally consistent, but with less effect in those with a nonviral etiology of HCC.

The global, open-label, phase III Imbrave150 trial (NCT03434379) included 501 patients with unresectable HCC who had not received prior systemic therapy. Patients were randomly assigned in a 2:1 ratio to receive either atezolizumab (1,200 mg intravenously [IV]) and bevacizumab (15mg/kg IV) every 3 weeks (n = 336) or sorafenib (400 mg PO bid) (n = 165). Eligibility criteria included intact liver function (Child-Pugh class A), and the study excluded patients with untreated or incompletely treated esophageal or gastric varices.[9]

Grade 3 or higher treatment-related adverse events occurred in 63% of patients in the atezolizumab-bevacizumab arm and 57% of patients in the sorafenib arm.[10]